MaSTherCell to Supply TxCell With Clinical Batches of Ovasave for Phase 2b Crohn’s Disease Study

MaSTherCell to Supply TxCell With Clinical Batches of Ovasave for Phase 2b Crohn’s Disease Study
Cell therapy and regenerative medicine provider, Orgenesis, Inc., recently disclosed that its wholly-owned subsidiary, MaSTherCell, a contract development and manufacturing organization (CDMO), has signed an agreement of understanding with TxCell in France. The memorandum covers the manufacturing of clinical supplies of Ovasave, the company’s leading therapeutic. Ovasave is classified as an antigen-specific autologous T-regulatory somatic cell treatment,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *